New drug combo shows promise in Hard-to-Treat sarcomas

NCT ID NCT03449901

Completed Disease control Sponsor: Washington University School of Medicine Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a drug called ADI-PEG 20 combined with two chemotherapy drugs (gemcitabine and docetaxel) in 98 people with soft tissue sarcoma, osteosarcoma, Ewing's sarcoma, or small cell lung cancer. The goal was to see if the combination could slow cancer growth better than standard treatment. The approach targets cancers that lack a specific protein, making them more sensitive to the therapy.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for EWING'S SARCOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Ewing sarcoma osteosarcoma sarcoma small cell lung carcinoma soft tissue sarcoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SOFT TISSUE SARCOMA

Contacts and locations

Locations

Columbia University Medical Center

New York, New York, 10032, United States
Sarcoma Oncology Center

Santa Monica, California, 90403, United States
Stanford Medicine

Palo Alto, California, 94304, United States
Washington University School of Medicine

St Louis, Missouri, 63110, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.